Brisken C. Hormonal control of alveolar development and its implications for breast carcinogenesis. Mammary Gland Biology Neoplasia, 2002; 7(1): 39-48.
 Hickey T, Robinson J, Carroll J, Tilley W. Minireview: The androgen receptor in breast tissues: growth inhibitor, tumor suppressor, oncogene. Molecular Endocrinology, 2012; 26(8): 1252-67.
 Polyak K. On the birth of breast cancer. Biochimica et Biophysica Acta (BBA). Review Cancer, 2001; 1552(1): 1-13.
 Jatoi I. Breast cancer adjuvant therapy: Time to consider its time-dependent effects. Clinical Oncology, 2011: 29.
 Bombonati1 A, Dennis CS. The molecular pathology of breast cancer progression. Pathology, 2011; 223: 307-17.
 University C. Breast cancer and environmental risk factors. Fact Sheet, 1997; 5: 5-10.
 Polyak K. Breast cancer: origins and evolution. Journal of Clinical Investegation, 2007; 117(11): 3155-63.
 Abbasi S. Estrogen receptor-beta gene polymorphism in women with breast cancer at the Imam Khomeini Hospital Complex, Iran. BMC Medical Genetic, 2010; 11: 109.
 Lichtenstein P, Holm N, Verkasalo P, et al. Environmental and heritable factors in the causation of cancer--analyses of cohorts of twins from Sweden, Denmark, and Finland. England Journal of Medecine, 2000; 343(2): 78-85.
 Singletary S. Rating the risk factors for breast cancer. Annal Surgary, 2003; 237(4): 474-82.
 Ripperger T, Gadzicki D, Meindl A, Schlegelberger B. Breast cancer susceptibility: current knowledge and implications for genetic counselling. Eurpean Journal of Human Genetic, 2009; 17(6): 722-31.
 Dunn L, Demichele A. Genomic predictors of outcome and treatment response in breast cancer. Molecular Diagnosis Therapy, 2009; 13(2): 73-90.
 Brody L, Biesecker B. Breast cancer susceptibility genes: BRCA1 and BRCA2. Medicine, 1998; 77(3): 208-26.
 Lawson JS, Heng B. Viruses and breast cancer. Cancers, 2010; 2: 752-72.
 Hulka B, Moorman P. Breast cancer: hormones and other risk factors. Maturitas, 2001; 38(1): 103-13.
 Gruber C, Tschugguel W, Schneeberger C, Huber J. Production and actions of estrogens. New England Journal of Medecin, 2002; 346: 340-52.
 Fu Y, Lian Y, Kim K, Zhang L, Hindle A, Brody F, et al. BP1 homeoprotein enhances metastatic potential in ER-negative breast cancer. Journal of Cancer, 2010; 1: 54-62.
 Mazaheri M. Molecular basis of anti-hormonal treatment and resistance in breast cancer Université de Toulouse, Université Toulouse III-Paul Sabatier; 2009.
 Buzdar A, Hortobagyi G. Update on endocrine therapy for breast cancer. Clinical Cancer Research, 1998; 4: 527-34.
 Yager J, Davidson N. Estrogen carcinogenesis in breast cancer. 2006; 354: 270-8.
 Garcia-Closas M, Chanock S. Genetic susceptibility loci for breast cancer by estrogen receptor status. Clinical Cancer Research, 2008; 14(24): 8000-9.
 Mazaheri M. Molecular basis of anti-hormonal treatment and resistance in breast cancer: Université de Toulouse, Université Toulouse III-Paul Sabatier; 2009.
 Pearce S, Jordan V. The biological role of estrogen receptors (alpha) and (beta) in cancer. Critical Review of Oncology and Hematology, 2004; 50(1): 3-22.
 Gronemeyer H. Transcription activation by estrogen and progesterone receptors. Ann Review Genetic, 1991; 25(1): 89-123.
 Monje P, Zanello S, Holick M, Boland R. Differential cellular localization of estrogen receptor (alpha) in uterine and mammary cells. Molecular and Cellular Endocrinology, 2001; 181: 117-29.
 Maruvada P, Baumann C, Hager G, Yen P. Dynamic shuttling and intranuclear mobility of nuclear hormone receptors. Journal of Biological Chemistry, 2003; 278: 12425-32.
 Reid G, Denger S, Kos M, Gannon F. Human estrogen receptor-a: regulation by synthesis, modification and degradation. Cellular and Molecular Life Science (CMLS), 2002; 59(5): 821-29.
 Saxena N, Sharma D. Epigenetic reactivation of estrogen receptor: promising tools for restoring response to endocrine therapy. Mol Cell Pharmacol, 2010; 2(5): 191-202.
 Kocanova S, Mazaheri M, Caze-Subra S, Bystricky K. Ligands specify estrogen receptor alpha nuclear localization and degradation. BMC Cell Biology, 2010; 11(1): 98-108.
 McKenna N, Lanz R, O'Malley B. Nuclear receptor coregulators. Cellular and Molecular Biology, 1999; 20: 321-44.
 Neeraj K, Saxena1, Sharma D. Epigenetic reactivation of estrogen receptor: Promising tools for restoring response to endocrine therapy. Molecular and Cellular Pharmacology, 2010; 2(5): 191-202.
 Buteau-Lozano H, Velasco G, Cristofari M, Balaguer P, Perrot-Applanat M. Xenoestrogens modulate vascular endothelial growth factor secretion in breast cancer cells through an estrogen receptor-dependent mechanism. Journal of Endocrinology, 2008; 196(2): 399-412.
 Fernandez S, Russo J. Estrogen and xenoestrogens in breast cancer. Toxicological Pathology, 2010; 38(1): 110-22.
 Beatson G. The treatment of inoperable cases of carcinoma of the mamma: suggestion for method of treatment, with illustrative case. The Lancet, 1896; 148(3802): 104-7.
 El Saghir N, Tfayli A, Hatoum H, Nachef Z, Dinh P, Awada A. Treatment of meta static breast cancer: State-of-the-art, subtypes andperspectives. Critical Review of Oncology and Hematology, 2011; 80(3): 433-49.
 Buzdar AU, Robertson JFR. Fulvestrant: Pharmacologic profile versus existing endocrine agents for the treatment of breast cancer. Annual of Pharmacotherapy,2006; 40(9): 1572-83.
 Ahmad A, Shahabuddin S, Sheikh S, Kale P, Krishnappa M, Rane R, et al. Endoxifen, a new cornerstone of breast cancer therapy: demonstration of safety, tolerability, and systemic bioavailability in healthy human subjects. Clinical Pharmacology Therapy, 2010; 88
 Love R, Desta Z, Flockhart D, Skaar T, Ogburn E, Ramamoorthy A, et al. CYP2D6 genotypes, endoxifen levels, and diseaserecurrence in 224 Filipino and Vietnamesewomen receiving adjuvant tamoxifen for operable breast cancer. Springer Plus, 2013; 2: 52-60.
 Ell P. The contribution of PET/CT to improved patient management. The British Journal of Radiology, 2014; 79(937): 32-6.
 Hertz D, McLeod H, Hoskins J. Pharmacogenetics of breast cancer therapies. Breast, 2009; 18: 59-63.
 Karn A, Jha AK, Shrestha S, Acharya B, Poudel S, Bhandari R. Tamoxifen for breast cancer. Journal of Nepal Medical Association, 2010; 49(177): 41-67.
 Howell A, DeFriend D, Blamey R, Robertson J, Walton P. Response to a specific antioestrogen (ICI 182780) in tamoxifen-resistant breast cancer. The Lancet. 1995; 345(8941): 29-30.
 Yao K, Lee E, Bentrem D, England G, Schafer J, O'Regan R. Antitumor action of physiological estradiol on tamoxifen-stimulated breast tumors grown in athymic mice. Clinical Cancer Research, 2000; 6(5): 2028-36.
 Ward A, Balwierz A, Zhang J, Küblbeck M, Pawitan Y, Hielscher T, et al. Re-expression of microRNA-375 reverses both tamoxifen resistance and accompanying EMT-like properties in breast cancer. Oncogene, 2013; 32(9): 1173-82.
 Pathiraja T, Stearns V, Oesterreich S. Epigenetic regulation in estrogen receptor positive breast cancer--role in treatment response. Journal of Mammary Gland Biology and Neoplasia, 2010; 15(1): 35-47.
 Kristensen L, Nielsen H, Hansen L. Epigenetics and cancer treatment. Europen Journal of Pharmacology, 2009; 625(1-3): 131-42.
 Hayes C, Spink D, Spink B, Cao J, Walker N, Sutter T. 17 beta-estradiol hydroxylation catalyzed by human cytochrome P450 1B1. Procceding National Academy Science, 1996; 93(18): 9776-81.
 Clarke R, Liu M, Bouker Kea. Antiestrogen resistance in breast cancer and the role of estrogen receptor signaling. Oncogene, 2003; 22(47): 7316-39.
 Levenson A, Catherino W, Jordan V. Estrogenic activity is increased for an antiestrogen by a natural mutation of the estrogen receptor. Journal of Steroid Biochemistry and Molecular Biology, 1997; 60(5-6): 261-8.
 Fox E, Davis R, Shupnik M. ER(beta) in breast cancer--Onlooker, passive player, or active protector? Steroids, 2008; 73(11): 1039-51.
 Anzick S, Kononen J, Walker Rea. AIB1, a steroid receptor coactivator amplified in breast and ovar cancer. Science, 1997; 277(5328): 965-8.
 Lavinsky R, Jepsen K, Heinzel Tea. Diverse signaling pathways modulate nuclear receptor recruitment of N-CoR and SMRT complexes. Procceding National Academy Science. 1998; 95(6): 2920-98.
 Zheng L, Zhao Y, Feng H, Liu Y. Endocrine resistance in breast cancer. Climacteric, 2014; 17(5): 522-8.
 Massarweh S, Schiff R. Resistance to endocrine therapy in breast cancer: exploiting estrogen receptor/growth factor signaling crosstalk. Endocrinal Rrelated Cancer, 2006; 13(1): 15-24.
 Zwart W, Griekspoor A, Berno V, Lakeman K, Jalink K, Mancini M. PKA-induced resistance to tamoxifen is associated with an altered orientation of ER towards co-activator SRC-1. The EMBO Journal, 2007; 26: 3534-44.